[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-mellitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-mellitis":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100604376","pilot-of-continuous-glucose-monitor-augmented-food-is-medicine-100604376",false,"NCT07148713","Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine","Pilot of a CGM-Augmented Food Is Medicine Intervention","ALIGN","Inclusion Criteria:\n\n* Able to complete study activities in English\n* Aged ≥18 years\n* Type 2 diabetes as defined by self-report and confirmed by ICD-10 codes\n\n  * Chart review will be conducted by the study team and a diagnosis of type 2 diabetes (E.11.xx) from either the problem list or a diagnosis linked to an encounter will be used as confirmation. Discrepancies in diagnosis codes will be resolved by review of provider notes within the past 3 years.\n* HbA1c \\> 8.0% in the last 12 months via point of care or venous measurement. If there are multiple values, the most recent one will be considered.\n* Receiving primary or specialty care within UNC Health as defined by at least one visit with a primary care provider or endocrine provider within the past year\n* Indication of a barrier to healthy eating consisting of report of food insecurity (defined as a score greater or equal to 1.0 on the 6-item USDA Food Security Survey Module (FSSM)) and\u002FOR nutrition insecurity (defined as more often than 'Rarely' on the One-Item Gretchen Swanson Nutrition Screener, OR more often than 'Not Very Hard' on the Two-item Nutrition Security Screener (NSS))\n\n  * Any positive screen on the FSSM, Gretchen Swanson Nutrition Screener, or NSS\n* No plans to move from the area for at least 4 months\n* Willing and able to provide written informed consent and participate in all study activities\n\nExclusion Criteria:\n\n* Type 1 or other diabetes\n* Use of insulin or secretagogues in the preceding 6 months\n* Use of CGM in the preceding 6 months\n* Inability to use CGM and related technology (e.g., the companion app), including lack of a smartphone that is compatible with Stelo (information on compatible phones available in Appendix 1) or known allergy to adhesive\n* Known psychosis or major psychiatric illness that prevents participation with study activities\n* Pregnancy or planned pregnancy in the next 4 months-glycemic targets are different for pregnant women compared to non-pregnant women with diabetes and our intervention is designed for non-pregnant glycemic targets\n* Participant in diabetes, nutrition, or weight research intervention in last 12 months","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is designed to test the feasibility and preliminary efficacy of a continuous glucose monitor (CGM)-augmented food is medicine (FIM) intervention for adults with type 2 diabetes and nutrition or food insecurity. This study will learn if a FIM intervention (\"intervention\") that includes access to real-time CGM and nutrition counseling can increase engagement, improve glycemic management, and support healthy eating in this population, compared to the FIM intervention alone (\"comparator\").\n\nAt the study baseline, participants will be randomized to either the intervention or the comparator arm for 16 weeks. The intervention will occur during the first 12 weeks (phase 1: intervention phase) and will be compared to a standard FIM approach without CGM or counseling. Phase 2 (extension phase) will last 4 weeks and will consist of all participants in the intervention and comparator arm receiving both FIM and CGM for self-directed use. The study will also explore participant experiences through a series of semi-structured interviews with a subset of randomly selected participants to identify opportunities for scaling the intervention to a broader population.",[27,28,29,30,31,32,33],"Nutrition","Type 2 Diabetes","T2DM","T2DM (Type 2 Diabetes Mellitus)","Diabetes Education","Diabetes Type 2","Diabetes Mellitis",[35,29,27,36,37,28,38,39],"Diabetes","Food is Medicine","Continuous glucose monitor","Food insecurity","Nutrition insecurity","RECRUITING","2025-11-10",{"date":43,"type":44},"2025-11-12","ACTUAL",{"date":46,"type":44},"2025-09-19",{"date":48,"type":21},"2026-06",{"name":50,"class":51},"University of North Carolina, Chapel Hill","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":52},"100586177","comparative-efficacy-of-metformin-and-berberine-among-tcf7l2-rs7903146-tt-vs-cc-genotype-carriers-with-type-2-diabetes-100586177","NCT06911983","Comparative Efficacy of Metformin and Berberine Among TCF7L2 (rs7903146) TT vs. CC Genotype Carriers With Type 2 Diabetes","Comparative Efficacy of Metformin and Berberine Among TCF7L2 (rs7903146) TT vs. CC Genotype Carriers With Type 2 Diabetes: A Pilot Randomized Clinical Study","Inclusion Criteria:\n\n* Adults aged 30-65 years;\n* Newly diagnosed T2DM ≤1 year;\n* Baseline HbA1c: 7.0-9.0% (53-75 mmol\u002Fmol);\n* No prior use of antihyperglycemic agents or ≤4 weeks of usage;\n* Willing to sign informed consent and undergo TCF7L2 genotyping;\n* TT or CC genotype (rs7903146)\n\nExclusion Criteria:\n\n* Severe comorbidities (hepatic, renal, cardiac dysfunction);\n* Pregnancy or lactation;\n* Known allergy or intolerance to metformin or berberine;\n* Participation in another clinical trial within the last 3 months;\n* TC genotype (excluded).","30 Years","65 Years",{"count":20,"type":21},[24],"This pilot 12-week randomized open-label study compares metformin and berberine in newly diagnosed type 2 diabetes patients stratified by the TCF7L2 (rs7903146) genotype (TT vs. CC). The primary goal is to assess changes in HbA1c between metformin and berberine treated groups within each genotype. Secondary outcomes include fasting and postprandial glucose, insulin levels, HOMA-IR, body weight\u002FBMI, lipid profile and adverse events.\n\nThe central hypothesis is that berberine, through its additional effect on TCF7L2-linked pathways, will provide superior glycemic control in high-risk TT carriers compared to metformin, whereas both treatments will yield comparable results in CC carriers. By enrolling only TT and CC genotypes, this study aims to estimate effect sizes and feasibility, guiding a future, larger-scale trial on genotype-tailored diabetes therapies.",[33],[67,68,69,70],"genetics","polymorphysm","supplements","berberine","NOT_YET_RECRUITING","2025-04-17",{"date":74,"type":44},"2025-04-20",{"date":76,"type":21},"2025-07-01",{"date":78,"type":21},"2026-03-01",{"name":80,"class":51},"S.LAB (SOLOWAYS)"]